Can simple blood tests predict kidney decline in ADPKD?

NCT ID NCT07217158

Ongoing Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study from Mayo Clinic is looking at 100 people with autosomal dominant polycystic kidney disease (ADPKD) to see if certain markers in the blood and urine can predict how fast their kidney disease gets worse. Researchers will measure kidney size and function over time and compare them to levels of specific molecules linked to cell stress and signaling. The goal is to find better ways to track disease progression, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to predict how fast kidney disease progresses in people with ADPKD, helping doctors plan care earlier.
What could go wrong: This is an observational study, not a treatment trial. It may not find clear links between the biomarkers and disease progression, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Contacts and locations

Locations

Mayo Clinic

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.